Clinical trial
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With…
NCT00321620 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00321620 |
|---|---|
| Title | Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer |
| Official title | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bone Metastases |
| Intervention type | Biological, Drug |
| Interventions | zoledronic acid, denosumab |
| Enrollment | 1,904 |
| Start date | Apr 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Feb 24, 2012 |
| First posted | May 4, 2006 |
| Last update posted | Aug 29, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: